HIFα isoform specific activities drive cell-type specificity of VHL-associated oncogenesis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41102155.
- Also identified by DOI 10.1038/s41467-025-64214-3 and PMC identifier 12533196.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Cancers arising from dysregulation of generally operative signaling pathways are often tissue specific, but the mechanisms underlying this paradox are poorly understood. Based on striking cell-type specificity, we postulated that these mechanisms must operate early in cancer development and set out to study them in a model of von Hippel Lindau (VHL) disease. Biallelic mutation of the VHL ubiquitin ligase leads to constitutive activation of hypoxia inducible factors HIF1A and HIF2A and is generally a truncal event in clear cell renal carcinoma. We used an oncogenic tagging strategy in which VHL-mutant cells are marked by tdTomato, enabling their observation, retrieval, and analysis early after VHL-inactivation. Here, we reveal markedly different consequences of HIF1A and HIF2A activation, but that both contribute to renal cell-type specific consequences of VHL-inactivation in the kidney. Early involvement of HIF2A in promoting proliferation within the proximal tubular epithelium supports therapeutic targeting of HIF2A early in VHL disease.
Medical subject headings
- Von Hippel-Lindau Tumor Suppressor Protein
- Basic Helix-Loop-Helix Proteins
- Hypoxia-Inducible Factor 1, alpha Subunit
- Carcinogenesis
- Kidney Neoplasms
- von Hippel-Lindau Disease